Sonoma Biotherapeutics, Inc., a clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases, received a $45 million milestone payment from Regeneron Pharmaceuticals under the companies’ autoimmune alliance.   In March 2023, Sonoma Bio and Regeneron entered a collaboration and license agreement to research, develop and commercialize Treg cell therapies for inflammatory bowel disease and two other undisclosed indications,...